{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:21:32Z","timestamp":1781900492412,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00228-024-03631-7","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T01:01:50Z","timestamp":1706144510000},"page":"563-573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs"],"prefix":"10.1007","volume":"80","author":[{"given":"Yueping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"12","key":"3631_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ada) and the European association for the study of diabetes (easd). Diabetologia 65(12):1925\u20131966. https:\/\/doi.org\/10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"issue":"18","key":"3631_CR2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 aha\/acc\/hfsa guideline for the management of heart failure: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"3","key":"3631_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, Chan J, Heerspink H, Hurst C et al (2023) Diabetes management in chronic kidney disease: synopsis of the kdigo 2022 clinical practice guideline update. ANN INTERN MED 176(3):381\u2013387. https:\/\/doi.org\/10.7326\/M22-2904","journal-title":"ANN INTERN MED"},{"key":"3631_CR4","doi-asserted-by":"publisher","unstructured":"Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S (2023) Unlocking the full potential of sglt2 inhibitors: expanding applications beyond glycemic control. INT J MOL SCI 24(7). https:\/\/doi.org\/10.3390\/ijms24076039","DOI":"10.3390\/ijms24076039"},{"key":"3631_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2023.10.003","author":"JH O\u2019Keefe","year":"2023","unstructured":"O\u2019Keefe JH, Weidling R, O\u2019Keefe EL, Franco WG (2023) Sglt inhibitors for improving healthspan and lifespan. PROG CARDIOVASC DIS. https:\/\/doi.org\/10.1016\/j.pcad.2023.10.003","journal-title":"PROG CARDIOVASC DIS"},{"key":"3631_CR6","doi-asserted-by":"publisher","first-page":"110082","DOI":"10.1016\/j.diabres.2022.110082","volume":"192","author":"WH Tsai","year":"2022","unstructured":"Tsai WH, Kong SK, Lin CL, Cheng KH, Cheng YT, Chien MN et al (2022) Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: a network meta-analysis. DIABETES RES CLIN PR 192:110082. https:\/\/doi.org\/10.1016\/j.diabres.2022.110082","journal-title":"DIABETES RES CLIN PR"},{"key":"3631_CR7","doi-asserted-by":"publisher","first-page":"735824","DOI":"10.3389\/fendo.2021.735824","volume":"12","author":"YS Zhang","year":"2021","unstructured":"Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC (2021) Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis. FRONT ENDOCRINOL 12:735824. https:\/\/doi.org\/10.3389\/fendo.2021.735824","journal-title":"FRONT ENDOCRINOL"},{"key":"3631_CR8","doi-asserted-by":"publisher","first-page":"825417","DOI":"10.3389\/fphar.2022.825417","volume":"13","author":"S Chai","year":"2022","unstructured":"Chai S, Liu F, Yang Z, Yu S, Liu Z, Yang Q et al (2022) Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks. FRONT PHARMACOL 13:825417. https:\/\/doi.org\/10.3389\/fphar.2022.825417","journal-title":"FRONT PHARMACOL"},{"key":"3631_CR9","doi-asserted-by":"publisher","first-page":"1238399","DOI":"10.3389\/fendo.2023.1238399","volume":"14","author":"CX Li","year":"2023","unstructured":"Li CX, Liu LY, Zhang CX, Geng XH, Gu SM, Wang YQ et al (2023) Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. FRONT ENDOCRINOL 14:1238399. https:\/\/doi.org\/10.3389\/fendo.2023.1238399","journal-title":"FRONT ENDOCRINOL"},{"issue":"5","key":"3631_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2215\/CJN.0000000000000115","volume":"18","author":"EL Fu","year":"2023","unstructured":"Fu EL, D\u2019Andrea E, Wexler DJ, Patorno E, Paik JM (2023) Safety of sodium-glucose cotransporter-2 inhibitors in patients with ckd and type 2 diabetes: population-based us cohort study. CLIN J AM SOC NEPHRO 18(5):592\u2013601. https:\/\/doi.org\/10.2215\/CJN.0000000000000115","journal-title":"CLIN J AM SOC NEPHRO"},{"issue":"3","key":"3631_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E (2023) Comparing effectiveness and safety of sglt2 inhibitors vs dpp-4 inhibitors in patients with type 2 diabetes and varying baseline hba1c levels. JAMA INTERN MED 183(3):242\u2013254. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6664","journal-title":"JAMA INTERN MED"},{"issue":"9","key":"3631_CR12","doi-asserted-by":"publisher","first-page":"e2335797","DOI":"10.1001\/jamanetworkopen.2023.35797","volume":"6","author":"HY Ko","year":"2023","unstructured":"Ko HY, Bea S, Jeong HE, Park S, Cho YM, Kong SH et al (2023) Sodium-glucose cotransporter 2 inhibitors vs incretin-based drugs and risk of fractures for type 2 diabetes. JAMA NETW OPEN 6(9):e2335797. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35797","journal-title":"JAMA NETW OPEN"},{"issue":"2","key":"3631_CR13","doi-asserted-by":"publisher","first-page":"101418","DOI":"10.1016\/j.diabet.2022.101418","volume":"49","author":"A Karasik","year":"2023","unstructured":"Karasik A, Lanzinger S, Chia-Hui TE, Yabe D, Kim DJ, Sheu WH et al (2023) Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in europe and asia: results from the empagliflozin comparative effectiveness and safety (emprise) study. DIABETES METAB 49(2):101418. https:\/\/doi.org\/10.1016\/j.diabet.2022.101418","journal-title":"DIABETES METAB"},{"key":"3631_CR14","doi-asserted-by":"publisher","first-page":"110576","DOI":"10.1016\/j.diabres.2023.110576","volume":"197","author":"D Lui","year":"2023","unstructured":"Lui D, Wu T, Tang E, Au I, Lee CH, Woo YC et al (2023) Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across egfr and albuminuria categories: a population-based study in hong kong. DIABETES RES CLIN PR 197:110576. https:\/\/doi.org\/10.1016\/j.diabres.2023.110576","journal-title":"DIABETES RES CLIN PR"},{"issue":"7","key":"3631_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLOS MED 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLOS MED"},{"key":"3631_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ-BRIT MED J 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ-BRIT MED J"},{"issue":"6","key":"3631_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","volume":"25","author":"D Cherney","year":"2023","unstructured":"Cherney D, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Powell DR et al (2023) Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. DIABETES OBES METAB 25(6):1646\u20131657. https:\/\/doi.org\/10.1111\/dom.15019","journal-title":"DIABETES OBES METAB"},{"issue":"3","key":"3631_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J et al (2022) The sglt2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. NAT MED 28(3):568\u2013574. https:\/\/doi.org\/10.1038\/s41591-021-01659-1","journal-title":"NAT MED"},{"issue":"4","key":"3631_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J et al (2022) The sglt2 inhibitor canagliflozin in heart failure: the chief-hf remote, patient-centered randomized trial. NAT MED 28(4):809\u2013813. https:\/\/doi.org\/10.1038\/s41591-022-01703-8","journal-title":"NAT MED"},{"issue":"4","key":"3631_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/dom.13631","volume":"21","author":"S Gallo","year":"2019","unstructured":"Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A et al (2019) Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week Vertis met trial. DIABETES OBES METAB 21(4):1027\u20131036. https:\/\/doi.org\/10.1111\/dom.13631","journal-title":"DIABETES OBES METAB"},{"issue":"1","key":"3631_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP et al (2018) Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the vertis renal randomized study. DIABETES THER 9(1):49\u201366. https:\/\/doi.org\/10.1007\/s13300-017-0337-5","journal-title":"DIABETES THER"},{"issue":"9","key":"3631_CR22","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343","volume":"41","author":"JB Buse","year":"2018","unstructured":"Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW et al (2018) Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American intandem1 study. Diabetes Care 41(9):1970\u20131980. https:\/\/doi.org\/10.2337\/dc18-0343","journal-title":"Diabetes Care"},{"issue":"6","key":"3631_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2337\/dc21-2034","volume":"45","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ et al (2022) Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials. Diabetes Care 45(6):1445\u20131452. https:\/\/doi.org\/10.2337\/dc21-2034","journal-title":"Diabetes Care"},{"issue":"7","key":"3631_CR24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2015) Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38(7):1218\u20131227. https:\/\/doi.org\/10.2337\/dc14-0315","journal-title":"Diabetes Care"},{"issue":"8","key":"3631_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/dom.12666","volume":"18","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Xu J, Parikh S, Johnsson E et al (2016) Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. DIABETES OBES METAB 18(8):766\u2013774. https:\/\/doi.org\/10.1111\/dom.12666","journal-title":"DIABETES OBES METAB"},{"issue":"8","key":"3631_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","volume":"37","author":"CS Kovacs","year":"2015","unstructured":"Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A et al (2015) Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. CLIN THER 37(8):1773\u20131788. https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.511","journal-title":"CLIN THER"},{"issue":"5","key":"3631_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. LANCET DIABETES ENDO 2(5):369\u2013384. https:\/\/doi.org\/10.1016\/S2213-8587(13)70208-0","journal-title":"LANCET DIABETES ENDO"},{"issue":"5","key":"3631_CR28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","volume":"57","author":"D Polidori","year":"2014","unstructured":"Polidori D, Mari A, Ferrannini E (2014) Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 57(5):891\u2013901. https:\/\/doi.org\/10.1007\/s00125-014-3196-x","journal-title":"Diabetologia"},{"issue":"3","key":"3631_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET DIABETES ENDO 1(3):208\u2013219. https:\/\/doi.org\/10.1016\/S2213-8587(13)70084-6","journal-title":"LANCET DIABETES ENDO"},{"issue":"12","key":"3631_CR30","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12):2582\u20132592. https:\/\/doi.org\/10.1007\/s00125-013-3039-1","journal-title":"Diabetologia"},{"issue":"6","key":"3631_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JJ Januzzi","year":"2017","unstructured":"Januzzi JJ, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M et al (2017) Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J AM COLL CARDIOL 70(6):704\u2013712. https:\/\/doi.org\/10.1016\/j.jacc.2017.06.016","journal-title":"J AM COLL CARDIOL"},{"issue":"9733","key":"3631_CR32","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223\u20132233. https:\/\/doi.org\/10.1016\/S0140-6736(10)60407-2","journal-title":"Lancet"},{"issue":"6","key":"3631_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K et al (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. ANN INTERN MED 156(6):405\u2013415. https:\/\/doi.org\/10.7326\/0003-4819-156-6-201203200-00003","journal-title":"ANN INTERN MED"},{"issue":"9","key":"3631_CR34","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Esterline R, Furtado R, Oscarsson J, Gasparyan SB, Koch GG et al (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with covid-19 (dare-19): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET DIABETES ENDO 9(9):586\u2013594. https:\/\/doi.org\/10.1016\/S2213-8587(21)00180-7","journal-title":"LANCET DIABETES ENDO"},{"issue":"2","key":"3631_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. NEW ENGL J MED 384(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"NEW ENGL J MED"},{"issue":"2","key":"3631_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. NEW ENGL J MED 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"NEW ENGL J MED"},{"issue":"16","key":"3631_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. NEW ENGL J MED 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"NEW ENGL J MED"},{"issue":"12","key":"3631_CR38","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray J, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. NEW ENGL J MED 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"NEW ENGL J MED"},{"issue":"2","key":"3631_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2023) Empagliflozin in patients with chronic kidney disease. NEW ENGL J MED 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"NEW ENGL J MED"},{"issue":"24","key":"3631_CR40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink H, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. NEW ENGL J MED 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"NEW ENGL J MED"},{"issue":"7","key":"3631_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEW ENGL J MED 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"NEW ENGL J MED"},{"issue":"15","key":"3631_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. NEW ENGL J MED 383(15):1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"NEW ENGL J MED"},{"issue":"15","key":"3631_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. NEW ENGL J MED 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"NEW ENGL J MED"},{"issue":"21","key":"3631_CR44","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"J McMurray","year":"2019","unstructured":"McMurray J, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. NEW ENGL J MED 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"NEW ENGL J MED"},{"issue":"15","key":"3631_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"H Heerspink","year":"2020","unstructured":"Heerspink H, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. NEW ENGL J MED 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"NEW ENGL J MED"},{"issue":"22","key":"3631_CR46","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEW ENGL J MED 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"NEW ENGL J MED"},{"issue":"4","key":"3631_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. NEW ENGL J MED 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"NEW ENGL J MED"},{"issue":"7","key":"3631_CR48","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/dom.14359","volume":"23","author":"D Patoulias","year":"2021","unstructured":"Patoulias D, Papadopoulos C, Boulmpou A, Doumas M (2021) Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: implications for the covid-19 pandemic. DIABETES OBES METAB 23(7):1696\u20131700. https:\/\/doi.org\/10.1111\/dom.14359","journal-title":"DIABETES OBES METAB"},{"issue":"1","key":"3631_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12020-021-02644-x","volume":"73","author":"M Qiu","year":"2021","unstructured":"Qiu M, Ding LL, Zhan ZL, Liu SY (2021) Use of sglt2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of sglt2 inhibitors. Endocrine 73(1):31\u201336. https:\/\/doi.org\/10.1007\/s12020-021-02644-x","journal-title":"Endocrine"},{"key":"3631_CR50","doi-asserted-by":"publisher","first-page":"743807","DOI":"10.3389\/fendo.2021.743807","volume":"12","author":"M Qiu","year":"2021","unstructured":"Qiu M, Zhao LM, Zhan ZL (2021) Comprehensive analysis of adverse events associated with sglt2is: a meta-analysis involving nine large randomized trials. FRONT ENDOCRINOL 12:743807. https:\/\/doi.org\/10.3389\/fendo.2021.743807","journal-title":"FRONT ENDOCRINOL"},{"issue":"5","key":"3631_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/FJC.0000000000001222","volume":"79","author":"HT Zou","year":"2022","unstructured":"Zou HT, Yang GH, Cai YJ, Chen H, Zheng XQ, Hu R (2022) Are high- or low-dose sglt2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis. J CARDIOVASC PHARM 79(5):655\u2013662. https:\/\/doi.org\/10.1097\/FJC.0000000000001222","journal-title":"J CARDIOVASC PHARM"},{"key":"3631_CR52","doi-asserted-by":"publisher","first-page":"724405","DOI":"10.3389\/fphar.2021.724405","volume":"12","author":"DG Yin","year":"2021","unstructured":"Yin DG, Qiu M, Duan XY (2021) Association between sglt2is and cardiovascular and respiratory diseases: a meta-analysis of large trials. FRONT PHARMACOL 12:724405. https:\/\/doi.org\/10.3389\/fphar.2021.724405","journal-title":"FRONT PHARMACOL"},{"issue":"5","key":"3631_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu O, Filion KB (2018) Sglt-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. ACTA DIABETOL 55(5):503\u2013514. https:\/\/doi.org\/10.1007\/s00592-018-1116-0","journal-title":"ACTA DIABETOL"},{"issue":"1","key":"3631_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12916-023-02765-2","volume":"21","author":"HE Jeong","year":"2023","unstructured":"Jeong HE, Park S, Noh Y, Bea S, Filion KB, Yu O et al (2023) Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study. BMC MED 21(1):47. https:\/\/doi.org\/10.1186\/s12916-023-02765-2","journal-title":"BMC MED"},{"issue":"6","key":"3631_CR55","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/ggi.14591","volume":"23","author":"T Saito","year":"2023","unstructured":"Saito T, Nojiri S, Kasai T, Hiratsuka Y, Ishijima M, Daida H (2023) Impact of sodium-glucose cotransporter-2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: a matched case-control study. GERIATR GERONTOL INT 23(6):418\u2013425. https:\/\/doi.org\/10.1111\/ggi.14591","journal-title":"GERIATR GERONTOL INT"},{"issue":"12","key":"3631_CR56","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","volume":"34","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang F, Zhang Y, Zhang J, Sheng Y, Wang W et al (2023) Effect of sglt2 inhibitors on fractures, Bmd, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos INT 34(12):2013\u20132025. https:\/\/doi.org\/10.1007\/s00198-023-06908-2","journal-title":"Osteoporos INT"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03631-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:34:21Z","timestamp":1710318861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03631-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3631"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03631-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required because this article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required because this article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}